Improving Fetal Monitoring
Designed to improve the standard of obstetric care, this new stylish design does not dominate the bedside, yet continues to offer a clear visual of the status of the fetus.
Designed to improve the standard of obstetric care, this new stylish design does not dominate the bedside, yet continues to offer a clear visual of the status of the fetus.
Obstetric anal sphincter injuries (OASIS) or 3rd/4th degree tears are a serious complication of childbirth that can lead to anal incontinence (AI). AI can have a devastating impact on a person’s quality of life and is perceived as a social stigma. Due to these childbirth related injuries, women are nine times more likely to develop AI compared to men.
Watch the video on how to start! Or download the brochure here.
Featuring talks from industry experts: Drug tocolysis: when and how? Prof. Dr. Werner Rath. University of Aachen and Kiel, Germany. Prediction of Preterm Delivery: looking at risk factors and biomarkers, the Belgium perspective. Dr. Caroline Van Holsbeke. ZOL, Belgium. Improving results: best practice in patient identificaion and routing. Prof. Dr. Ildar Fatkullin. University of Kazan, Russia.
PartoSure is the only Time to Delivery test with both high PPV and NPV, proven by consistent performance results across studies and geographies to assess the risk of preterm birth. It is a rapid bedside test that can be performed by doctors, nurses and midwives, with or without speculum examination. For a limited time In Vitro Technologies are giving away FREE PartoSure tests.
Approximately 25,000 Australian babies are born prematurely every year. The BabyBloom incubator provides a warm and safe place to grow and develop for the most vulnerable premature infants while keeping mother as close as possible.
In Vitro Technologies is proud to announce TGA approval for Cytocell’s Telomere range
In Vitro Technologies is proud to announce TGA approval for Cytocell’s Prenatal range
Research shows that conventional diagnostic tests, such as nitrazine (pH), ferning, pooling and ultrasound can be inaccurate and invasive. In fact Neil 2010 shows that 47% of the time clinicians are not confident in their diagnosis of PROM based on history and examination alone. The current biomarker tests to aid in detection of PROM give clinicians the certainty they need to make a confident diagnosis, quickly and easily.
Comparison of a novel test for placental alpha macroglobulin-1 with fetal fibronectin and cervical length measurement for the prediction of imminent spontaneous preterm delivery in patients with threatened preterm labor.